Comparación del ensayo de digoxina con el sistema Architect ®i1000sr respecto al sistema AxSYM® / Comparing the Digoxin Test With the Architect ®i1000sr System With Respect to the AxSYM® System

Objetivo Evaluar en muestras séricas la técnica empleada por el autoanalizador Architect® i1000sr para la determinación de digoxina respecto al ensayo desarrollado para AxSYM® mediante enzimoinmuno análisis de micropartículas (DigoxinII).Método Análisis prospectivo de las muestras procedentes de 100 solicitudes de monitorización de pacientes en tratamiento con digoxina. Las muestras fueron procesadas en AxSYM® y Architect®. Las técnicas se evaluaron mediante el coeficiente de regresión lineal, el coeficiente de determinación, el error absoluto medio, el error cuadrático medio de predicción y el método de Bland-Altman. Resultados Las concentraciones séricas mostraron un coeficiente de correlación de 0,93. La diferencia se aproxima al 40% para concentraciones entre 0,8 y 2 ng/ml y al 20% en el resto de muestras analizadas. Conclusiones El sistema Architect® es preciso pero inexacto, en una magnitud inaceptable desde el punto de vista de la monitorización clínica respecto al AxSYM®(AU)

Objective To assess the technique employed by the autoanalyser Architect® i1000sr to determine digoxin in serum samples, compared with the assay developed for AsSYM® using microparticle enzyme immunoassay (Digoxin II).Method A prospective analysis of the samples from 100 requests to monitor patients being treated with digoxin. The samples were processed in AxSYM® and Architect®. The techniques were assessed using the linear regression coefficient, determination coefficient, mean absolute error, mean squared prediction error and the Bland-Altman method. Results The serum levels showed a correlation coefficient of 0.93. There was nearly a 40% difference for the concentrations between 0.8 and 2ng/ml and nearly 20% in the rest of the samples analysed. Conclusions The Architect® system is precise; however, from a clinical monitoring point of view, it is unacceptably inaccurate when compared with the AxSYM® (AU)

Comparing the digoxin test with the Architect® i1000sr system with respect to the AxSYM® system.

OBJECTIVE: To assess the technique employed by the autoanalyser Architect® i1000sr to determine digoxin in serum samples, compared with the assay developed for AsSYM® using microparticle enzyme immunoassay (DigoxinII). METHOD: A prospective analysis of the samples from 100 requests to monitor patients being treated with digoxin. The samples were processed in AxSYM® and Architect®. The techniques were assessed using the linear regression coefficient, determination coefficient, mean absolute error, mean squared prediction error and the Bland-Altman method. RESULTS: The serum levels showed a correlation coefficient of 0.93. There was nearly a 40% difference for the concentrations between 0.8 and 2 ng/ml and nearly 20% in the rest of the samples analysed. CONCLUSIONS: The Architect® system is precise; however, from a clinical monitoring point of view, it is unacceptably inaccurate when compared with the AxSYM®.